Advanced searches left 3/3

Alpelisib - PubMed

Summarized by Plex Scholar
Last Updated: 03 June 2022

* If you want to update the article please login/register

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.

"ALPHABET is a randomized phase III trial evaluating alpelisib + trastuzumab with or without fulvestrant in previously treated HER2-positive PIK3CA-mutated advanced breast cancer in previously treated HER2-positive HER2-mutated advanced breast cancer. " Patients will be included in two cohorts based on hormone receptor status. Patients in the HR-negative cohort will be treated with trastuzumab + almisib, and patients in the HR-positive cohort will be treated with the same care as the fulvestrant. ".

Source link: https://doi.org/10.2217/fon-2022-0045

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions